Johnson & Johnson JNJ
NYSE JNJ
$269.99 -0.22 (-0.08%)
At close: Sep 18, 2026 · 4:00 PM EDT

Johnson & Johnson (JNJ) Liabilities from Discontinued Operations (2023)

Johnson & Johnson's (JNJ) quarterly Liabilities from Discontinued Operations came in at $3.6 billion in Q1 2023.

Analysis

Johnson & Johnson (JNJ) Liabilities from Discontinued Operations (2023) Analysis & Trends

Johnson & Johnson has disclosed Liabilities from Discontinued Operations across 1 years of filings, most recently posting $3.6 billion for Q1 2023.

  • In Q1 2023, Liabilities from Discontinued Operations changed N/A year-over-year to $3.6 billion; the TTM figure through Jan 2023 stood at $3.6 billion (changed N/A YoY), while the FY2023 annual figure was $3.6 billion, changed N/A from the prior year.
  • Liabilities from Discontinued Operations came in at $3.6 billion for Q1 2023 at Johnson & Johnson.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of $3.6 billion in Q1 2023 to a low of $3.6 billion in Q1 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 650.65 Bn 629.89 Bn 17.26 Bn
2 AbbVie 466.34 Bn 459.82 Bn 12.70 Bn
3 Merck 362.11 Bn 355.02 Bn 12.21 Bn
4 Novartis Ag 267.81 Bn 260.52 Bn 11.24 Bn
5 Pfizer 157.31 Bn 145.91 Bn 10.94 Bn
6 Bristol Myers Squibb 128.75 Bn 117.69 Bn 9.25 Bn
7 Sanofi 51.80 Bn 44.84 Bn 10.79 Bn
8 Revolution Medicines 40.91 Bn 40.91 Bn -
9 BeOne Medicines 39.65 Bn 34.55 Bn 1.53 Bn
10 Incyte 25.18 Bn 20.65 Bn 1.57 Bn
Historic Data

Historic Data

Download Data
DateValue
Jan 1, 2023 3.59 Bn